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Abstract
Background: Pulmonary arterial hypertension (PAH) complicates the course of systemic sclerosis (SSc) and is associated
with poor prognosis. The elevation of systolic pulmonary arterial pressure (sPAP) during exercise in patients with SSc
with normal resting haemodynamics may anticipate the development of PAH. Exercise echocardiography (ExEcho) has
been proposed as a useful technique to identify exercise-induced increases in sPAP, but it is unclear how to clinically
interpret these findings. In this systematic review, we summarize the available evidence on the role of exercise
echocardiography to estimate exercise-induced elevations in pulmonary and left heart filling pressures in patients
with systemic sclerosis.
Methods: We conducted a systematic review of the literature using MEDLINE, Cochrane Library and Web of
Knowledge, using the vocabulary terms: (‘systemic sclerosis’ OR ‘scleroderma’) AND (‘exercise echocardiography’)
AND (‘pulmonary hypertension’). Studies including patients with SSc without a prior diagnosis of PAH, and subjected to
exercise echocardiography were included. All searches were limited to English and were augmented by review of
bibliographic references from the included studies. The quality of evidence was assessed by the Effective Public Health
Practice Project system.
Results: We identified 15 studies enrolling 1242 patients, who were mostly middle-aged and female. Several exercise
methods were used (cycloergometer, treadmill and Master’s two step), with different protocols and positions (supine,
semi-supine, upright); definition of a positive test also varied widely. Resting estimated sPAP levels varied from 18 to
35 mm Hg, all in the normal range. The weighted means for estimated sPAP were 22.2 ± 2.9 mmHg at rest and 43.0 ±
4.3 mmHg on exercise; more than half of the studies reported mean exercise sPAP ≥40 mmHg. The assessment of left
ventricular diastolic function on peak exercise was reported in a minority of studies; however, when assessed, surrogate
variables of left ventricular (LV) diastolic dysfunction were associated with higher sPAP on exercise.
Conclusions: We found very high heterogeneity in the methods, the protocols and the estimated sPAP response to
exercise. LV diastolic dysfunction was common and was associated with greater elevation of sPAP on exercise.
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Background
Systemic sclerosis (SSc) is an autoimmune disorder charac-
terised by autoantibody production, microvascular lesions
and collagen deposition [1] and can be complicated by
pulmonary arterial hypertension (PAH) in 8 to 20 % of
patients [2]. PAH remodelling affects the small pulmonary
arteries, leading to progressive increase in pulmonary vas-
cular resistance (PVR) and right heart failure [3]. Import-
antly, histopathological evidence of pulmonary arteriopathy
has been reported in up to 72 % of patients with SSc,
raising the possibility that subclinical features are present
well before the PAH diagnosis [4]. Therefore, early diagno-
sis is of importance, not only because of the rapid progres-
sion of the disease but also because it is critical to initiate
early treatment [5].
Echocardiography is a useful tool for pulmonary
hypertension (PH) screening, as it estimates systolic
PAP (sPAP), assesses right ventricular remodelling,
identifies morphological abnormalities that can indicate
the aetiology and may be used to evaluate treatment ef-
fectiveness [6]. However, a resting echocardiogram has
limited accuracy to diagnose elevations in pulmonary
pressures in SSc [7–9]. Stress tests performed during
exercise have been used increasingly in cardiology to
better characterise haemodynamic changes and there-
fore, a strong rationale exists to suggest that reduced
pulmonary vascular reserve may signal a subclinical
phase of pulmonary vascular disease (PVD) [10]. The
definition of exercise-induced PH (EIPH) has been
present in former PH guidelines, being defined by a
mean PAP (mPAP) >30 mmHg. However, it has been
abandoned due to lack of standardisation, prognostic
impact assessment and overlap with normal subjects
[11]. Nonetheless, performing an exercise echocardio-
gram may be an advantageous approach, as it allows
not only estimation of exercise-induced changes in
sPAP but also quantification of changes in cardiac out-
put (CO) and left ventricular (LV) diastolic filling pres-
sures, two determinants of variation in pulmonary
pressure. Some authors suggest that this early exercise
PAH phase is more amenable to treatment; others
suggest it may be stable with no pathological implica-
tions [12, 13].
In this systematic review, we summarize the available
evidence on the role of exercise echocardiography to
estimate exercise-induced elevations in pulmonary pres-
sures and in left heart filling pressures in patients with
SSc without resting PH.
Methods
The methods used conformed to the Meta-analysis of Ob-
servational Studies in Epidemiology [14] and the Cochrane
Collaboration [15] recommendations.
Selection criteria and search strategy
The literature search was conducted between January
2013 and December 2015 and comprised peer-reviewed
original research that investigated estimated EIPH as a
primary endpoint in patients with SSc using exercise
echocardiography. The search resources included MED-
LINE, Cochrane Library and Web of Knowledge, using
the search terms: (‘systemic sclerosis’ OR ‘scleroderma’)
AND (‘exercise echocardiography’) AND (‘pulmonary
hypertension’). Studies that were already known to the
authors of this review (based on previous work or famil-
iarity with the research area) were also included in the
review. The search was limited to English language arti-
cles published from 1995 onwards. Publications report-
ing no original data or without a clear description of the
research methods were excluded. Studies that did not
present estimated sPAP results for patients with SSc
were excluded. Conference abstracts or results posted in
trial registries were excluded. The grey literature was not
searched.
Data extraction and assessment
Study selection was performed by the investigators RB
(cardiologist) and SS (rheumatologist). References were
managed using Mendeley Desktop software (V.1.12.3).
We contacted the authors who reported sPAP by groups
of patients defined by a cutoff for exercise-induced sPAP,
but not for overall patients. Retrieved papers were hand-
searched for additional references. Details of the litera-
ture search process are outlined in the flow chart (Fig. 1).
Eligible studies included adult (18 years old or more)
patients with SSc (either diffuse or limited), subjected to
a stress protocol with exercise echocardiography. Pa-
tients were enrolled consecutively in all but one study,
where only patients at high risk of developing PAH were
included. As the main goal of exercise echocardiography
in SSc is to identify patients with pre-capillary (PAH)
elevations in pulmonary pressures, most authors aimed
to exclude patients at high risk of group-2 PH, as those
with uncontrolled systemic hypertension or a history or
evidence of significant cardiovascular or lung disease
(including coronary artery disease, LV hypertrophy,
myocardial ischaemia and severe valvular conditions).
A prior PAH diagnosis was also a criterion for study
exclusion.
All studies had a similar design. Patients were submitted
to echocardiography at rest (before exercise) and during
or immediately (within the first minute) after exercise.
The following variables were extracted when available:
year of publication, sample size, gender ratio, age, lung
function test parameters (forced vital capacity (FVC),
forced expiratory volume in the first second (FEV1) and
total lung capacity (TLC)), carbon monoxide diffusion
capacity (DLCO), type and date of SSc diagnosis, exercise
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method, time of exercise-induced estimated sPAP measure-
ment, maximum achieved workload in metabolic equiva-
lent of task (MET), patient position (supine or upright),
feasibility and intra and inter-observer variability (the latter
two parameters are presented in Additional file 1). Cardio-
vascular variables collected included estimated resting right
atrial pressure (RAP), tricuspid regurgitation-derived
estimated sPAP (at rest and peak exercise), heart rate
(HR) (at rest and peak exercise), estimated CO and car-
diac index (CI) (at rest and peak exercise) and estimated
pulmonary vascular resistance (PVR). In addition, diastolic
dysfunction markers were retrieved when available,
namely the ratio of early diastolic (E) and late diastolic (A)
transvalvular velocities (E/A) for each ventricle and the
ratio of early diastolic (E) and tissue Doppler-derived early
(e’) and atrial (a’) diastolic mitral annular velocity to early
diastolic (E) wave (E/e’). All data retrieved from the stu-
dies were relevant to the population characteristics, study
design, type of exercise endured and outcomes of interest.
In the scope of this review, the weighted mean and stan-
dard deviation for estimated sPAP (both at rest and peak
exercise) was also calculated.
Grading the quality of evidence of included studies
The Effective Public Health Practice Project (EPHPP) was
used by two of the authors (RB and SS) to rate the quality
of the evidence in the reviewed studies (Additional file 2)
[16]. Each study was assigned a score category of
strong, moderate or weak. Studies were graded by inde-
pendent reviews; when the original ratings disagreed,
they underwent a resolution review consensus. Double
entry of data was performed for three studies (20 % of
studies) and demonstrated a high level of accuracy
(98.7 %).
Results
A total of 78 publications were identified in the litera-
ture search. Of these, 19 were retrieved and analysed for
eligibility. A total of 15 studies were eligible for inclusion
in the review, and these were published between 1996
and 2015 (Fig. 1) [8, 17–30]. The characteristics of each
eligible study are presented in Table 1.
Demographic variables
The demographic characteristics are presented in Table 1.
A total of 1242 patients was assessed, with a large female
majority (range 76–100 %). The mean age in each study
ranged from 50–58 years and the mean time since SSc
diagnosis varied from 16 months to 12 years.
Stress protocols and measurements
Exercise echocardiography protocols and maximum
workload levels are described in Additional file 3. Of the
selected studies, 10 used a cycloergometer in the supine
or semi-supine position. Half of the studies estimated
exercise-induced sPAP immediately after or within one to
two minutes after exercise. HR was measured in 10 of the
selected studies. At rest, mean HR ranged between 71 and
82 bpm. Mean peak exercise HR varied between 115 and
150 bpm, signalling for moderate intensity exercise, given
the mean age of the population (54 years) and the expected
maximum HR for this age group (approximately 166 bpm).
Mean estimated sPAP is shown by study in Fig. 2.
Resting sPAP varied from 18–35 mmHg, all in the nor-
mal range. At peak exercise, mean sPAP ranged from
30–51 mmHg, with half of the studies reporting a mean
exercise sPAP ≥40 mmHg (Fig. 3). The weighted means
for estimated sPAP were 22.2 ± 2.9 mmHg at rest and
43.0 ± 4.3 mmHg at peak exercise. Most of the studies
Fig. 1 Search strategy and exclusion process for studies on exercise echocardiography in patients with systemic sclerosis (SSc). RHC: right
heart catheterization
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defined a minimum cutoff for EIPH that would define a
clinically relevant hypertensive response (a “positive
test”) for the exercise echocardiographic study. These
thresholds are shown in Additional file 4; the proportion
of positive tests ranged from 12–67 %.
Patients who exercised in an upright position on a
treadmill had numerically smaller elevation in sPAP than
patients assessed on a cycloergometer in a semi-supine
position (40 ± 7 vs. 47 ± 4 mmHg) (Additional file 5).
However, this might be due to the fact that upright
echocardiographic assessments of patients on the tread-
mill were always performed immediately after exercise. In
the studies where measurements were taken at peak exer-
cise, mean sPAP was 45 ± 5 mmHg, whereas in studies
were it was collected immediately after exercise was 40 ±
3 mmHg.
Left ventricular diastolic dysfunction markers
As SSc commonly affects the LV, the elevation of sPAP
during exercise might also be due to backward trans-
mission of elevated LV end-diastolic pressure (LVEDP).
Therefore, the assessment of a surrogate of LVEDP is
critical during the exercise test. Table 2 shows the
results from eight studies that reported these markers
among patients with and without positive tests in the
exercise echocardiogram in resting conditions (described
in Additional file 5 for each study). Most studies report
signs of resting LV diastolic dysfunction in the group of
patients who exhibited EIPH. Only three studies reported
LV E/e’ during peak exercise; all demonstrated a higher
exercise E/e’ in the patients with a positive exercise test.
Cardiac output, cardiac index and pulmonary vascular
resistance
Table 3 shows the studies that evaluated CO, CI and
PVR at rest and during/after exercise, with some per-
forming comparisons between patients with and without
a positive test. Baptista et al. [18] observed higher mean
resting CO in patients with positive tests. Suzuki et al.
and Voilliot et al. [28, 29] also observed higher mean
PVR in patients with positive tests, both for resting and
peak exercise PVR. Gargani et al. [23] also observed a
difference, but for peak exercise PVR only and they also
measured the ratio between changes in mean PAP
(mPAP) and changes in CO (mPAP/CO) induced by
exercise. Patients with positive tests had higher ratios
compared with the remaining patients (p < 0.05). D’Alto
et al. [22] also identified higher ΔsPAP/ΔCI ratios in
patients with SSc, compared with controls; Voilliot et al.
[29] demonstrated positive correlation between PVR and
exercise sPAP.
Lung function tests
DLCO and spirometry measures are presented in Additional
file 5. On evaluating the association between these parame-
ters and sPAP, Steen et al. [27] reported that patients with
DLCO <50 % or with FVC %/DLCO ratio >1.6 were more
likely to have an increase in sPAP ≥20 mmHg at peak
Table 1 Main characteristics of studies and patients
First author Publication year Condition Sample size Female gender (%) Age (years) Mean time since diagnosis Enrolment criteria
Mininni [25] 1996 SSc 9 78 % 56 27 m Consecutive
Alkotob [17] 2006 SSc 65 86 % 51 — Consecutive
Collinsa[21] 2006 DSSc 9 100 % 59 — Consecutive
Collinsb[21] 2006 LSSc 10 100 % 52 —
Pignone [26] 2007 LSSc 27 89 % 50 7 y Consecutive
Huez [24] 2007 SSc 8 92 % 54 16 m Consecutive
Callejas-Rubio [29] 2008 SSc 41 – 53 9 y Consecutive
Steen [27] 2008 SSc 54 94 % 53 — At high risk of PHd
Reichenberger [8] 2009 SSc 33 94 % 54 9 y Consecutive
D’Alto [22] 2010 SSc 172 90 % 52 — Consecutive
Ciurzynski [20] 2011 SSc 67 96 % 57 — Consecutive
Baptista [18] 2013 SSc 23 96 % 58 — Consecutive
Gargani [23] 2013 SSc 164 91 % 58 11 y Consecutive
Voilliot [29] 2014 SSc 45 76 % 54 — Consecutive
Suzuki [28] 2014 SSc 494 89 % 56 — Consecutive
Nagelc[30] 2015 SSc 21 84 % 58 12 y Consecutive
Quantitative variables (age) reported as means. Female and male patients represented by counts. aResults for patients with diffuse systemic sclerosis (DSSc).
bRresults for patients with limited systemic sclerosis (LSSc). cResults are for the full population studied (including patients unaware of having pulmonary
hypertension). dDyspnea on exertion, carbon monoxide diffusion capacity (DLCO) <60 % of predicted, forced vital capacity (FVC) <60 % of predicted, FVC %/DLCO
% >1.6, or resting right ventricular systolic pressure on echocardiogram >30 mmHg but <50 mmHg. m months, SSc systemic sclerosis, y years
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exercise (p < 0.001). Callejas-Rubio et al. [19] also observed
negative correlation between exercise sPAP and DLCO.
Discussion
We conducted a systematic review of the scientific litera-
ture assessing estimated sPAP by echocardiography during
exercise in patients with SSc. The results demonstrate
very high heterogeneity in (1) the methodology used to
exercise the patients and to estimate pressures, (2) the de-
finition of what is a positive response and (3) the assess-
ment of the LV diastolic performance at rest and during
exercise. Further, robust outcome data from patients with
EIPH are also lacking, making it difficult to establish prog-
nostic correlation.
Methodology of the test
Several exercise methods, positions and protocols were
used among the studies. It is well-known that the cardio-
pulmonary circulatory responses are different if patients
exercise in the supine or upright position and may relate
differently to symptoms; also, Doppler-derived parameters
can change with position and are challenging to assess in
the upright position [31–33]. However, we observed
several methods (cycloergometer, Master’s two step and
treadmill) and several positions (upright, supine and semi-
supine) used for exercise. Moreover, the different stress
protocols did not specify a predefined level of exertion to
be achieved to define a test as being positive, as in other
clinical scenarios such as coronary ischaemic disease, in a
classical treadmill test. In combination, these factors may
have accounted for the significant variability found in the
workload and peak exercise heart rate among the different
studies, and consequently, in the increased cardiac work
necessary to elicit a significant haemodynamic response.
Besides different workloads, Doppler-derived parameters
can change with position. For instance, when a patient
moves from the supine to the upright position, the E/e’ ra-
tio can change, as both parameters are preload-dependent
[34]. Additionally, correct Doppler assessment of the tri-
cuspid regurgitant velocity needs correct alignment of the
Doppler beam, something that can be difficult to achieve
in a patient exercising upright on a treadmill. Therefore,
the most reproducible approach is probably semi-supine
exercise on a cycloergometer with a ramped stress proto-
col, as recently proposed [35].
Another important aspect is the timing of imaging
acquisition. In most, but not all studies, estimated pres-
sures were collected during and at peak exercise, while
the patient was still exercising. However, some authors
assessed the patient one or two minutes after the end
of exercise. CO and heart rate pressure rapidly return
to normal after cessation of exertion (due to reversal of
splanchnic vasoconstriction and decreased venous re-
turn), and these findings may underestimate sPAP ele-
vation (or the severity of diastolic dysfunction) [36]. In
comparison with the other studies, the low proportion
of patients with a positive test reported by Ciurzynski
et al. may be due to the fact that sPAP was not
measured during but after exercise [31–33]. Using a
ramp protocol with a cycloergometer, the load can be
Fig. 3 Median systolic pulmonary arterial pressure (sPAP) (with
interquartile range) estimated by exercise echocardiography in
resting and peak exercise conditions for each study
Fig. 2 Mean pulmonary arterial systolic pressure by study. Results
from Alkotob et al. are divided into (a) patients with pulmonary fibrosis
and (b) patients without pulmonary fibrosis. Results from Collins et al are
divided into (a) patients with diffuse systemic sclerosis and (b) patients
with limited systemic sclerosis. The weighted mean for estimated systolic
pulmonary arterial pressure (sPAP) was 22.2 ± 2.9 mmHg at rest and
43.0 ± 4.3 mmHg at peak exercise
Baptista et al. Arthritis Research & Therapy  (2016) 18:153 Page 5 of 11
Table 2 Echocardiographic diastolic dysfunction markers
First author
Condition Alkotob
(n = 65)
Pignone (n = 27) Huez
(n = 25)
D’Alto
(n = 172)
Baptista (n = 23) Gargani (n = 164) Voilliot (n = 45) Suzuki (n = 494)
Total Total ≤40 mmHg >40 mmHg Total Total Total <50
mHg
≥50 mmHg <50 mmHg ≥50 mmHg Total ≤50 mmHg >50 mmHg Total <50 mmHg ≥50 mmHg
Rest RV
E/A
0.9 1.0* 0.7*
LV
E/A
1.2 1.1 1.2 1.0 1.3 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.2* 1.1*
E/e’ 10.2 9.9 10.5 6.6* 7.5* 6.0 5.5* 6.8* 9.6 9.2* 10.7*
Exercise RV
E/A
0.7
LV
E/A
1.2 1.3 1.1 1.1 1.1 1.0
E/e’ 10.0 9.4 10.5 6.8 5.7* 9.2* 10.7 10.3* 11.8*
Results presented as means. *Comparison between patients with maximum exercise-induced systolic pulmonary arterial pressure (sPAP) <50 mmHg and ≥50 mmHg statistically significantly different (p < 0.05). E/A ratio
of early diastolic (E) and late diastolic (A) transvalvular velocities, E/e’ ratio of early diastolic (E) and early diastolic mitral annular velocity (e’), LV left ventricle, RV right ventricle
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maintained constant over approximately three minutes
(at a pedalling rate of 55–65 bpm), enabling imaging
acquisition during peak exercise (or when symptoms
develop) instead of post-exercise measurements [35].
Interpretation of an exercise echocardiography test
Importantly, exercise sPAP cannot be interpreted without
information on two other determinants of pressure: flow
and LVEDP [37]. Pulmonary flow was reported in six
studies. In comparison to baseline CO, peak exercise CO
ranged between twofold and threefold the baseline value,
a small increase taking into consideration the expected in-
crease in CO in healthy subjects (fourfold to tenfold) [38].
This may signify either (1) a limited capacity in patients
with SSc to increase the CO during exercise or (2) an
inability of patients with SSc to exercise to a higher work-
load due to other mechanisms such as lung fibrosis,
osteoarticular issues, anaemia or deconditioning.
In general, the mean increase in sPAP across all studies
was 15 mmHg, to a weighted mean level of 43 mmHg;
most studies reported a value >40 mmHg. This elevation
in pressure is probably higher than would be expected
from the concomitant elevation in CO in this group of
patients with SSc, taking into consideration that in normal
individuals, exercise leads to smaller increases in sPAP
(mean 34.3 ± 7.5 mmHg) under large elevations of CO
(approximately 20 L.min-1) [38]. The importance of taking
CO into consideration when reporting exercise haemo-
dynamics is of paramount importance. In a study by
Argiento et al., 19 of 25 normal individuals had an eleva-
tion of estimated sPAP >40 mmHg. However, the mean
CO at peak exercise was 18.0 ± 4.2 L.min-1 [39], much
higher than the values achieved by the patients with SSc.
Therefore, for a CO <8–10 L.min-1 (similar to the ones
reported in the SSc studies we reviewed), mPAP should be
<30 mmHg (corresponding to an sPAP of approximately
47 mmHg), a threshold surpassed in the majority of the
studies performed in patients with SSc.
LV diastolic dysfunction is a critical determinant of
EIPH. As the LVEDP can contribute with more than 75 %
to sPAP during exercise in patients with resting PH due to
LV diastolic dysfunction [40], any analysis of exercise
sPAP without concomitant assessment of a surrogate of
LVEDP is difficult to interpret [41]. The studies that ana-
lysed resting and exercise LV diastolic parameters mostly
used E/e’ as a marker of diastolic function [42]. Although
arguably useful in the resting estimation of LV filling pres-
sures, the use of E/e’ in exercise protocols is debatable and
used in isolation, E/e’ is probably not sufficient to form
conclusions about exercise-induced diastolic dysfunction
[35, 43]. However, taking into consideration those limita-
tions, most studies found that higher elevations of sPAP
were associated with higher levels of either resting or peak
E/e’, and many conclude that there is an association
Table 3 Echocardiographic-derived cardiac output, cardiac index and pulmonary vascular resistance
First author Resting CO (L.min1) Exercise CO (L.min1) Resting CI (L.min1.m2) Exercise CI (L.min1.m2) Resting PVR (WU) Exercise PVR (WU)
Huez
Total 3.0 8.7 2.9
D’Alto
Total 3.0 5.8
Baptista
Total 3.6 9.2
sPAP <50 mmHg 3.8* 8.5
sPAP ≥50 mmHg 5.1* 9.9
Suzuki
Total 5.5 7.6 1.7 1.9
sPAP <50 mmHg 5.5 7.6 1.6* 1.8*
sPAP ≥50 mmHg 5.5 7.6 1.9* 2.3*
Voilliot
Total 3.7 7.2 1.9 2.5
sPAP ≥50 mmHg 3.9 7.7 1.4* 2.1*
sPAP >50 mmHg 3.5 6.5 2.6* 3.6*
Gargani
sPAP <50 mmHg 2.5 4.6 1.7 2.0*
sPAP ≥50 mmHg 2.7 4.9 1.7 2.3*
Results are presented as means. *Comparison between patients with maximum exercise-induced systolic pulmonary arterial pressure (sPAP) <50 mmHg and
≥50 mmHg statistically significantly different (p < 0.05). CI cardiac index, CO cardiac output, PVR pulmonary vascular resistance, WU Wood units
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between impaired relaxation of the LV and an increase in
sPAP, both at rest and on peak exercise. Therefore, one
cannot diagnose the presence of pulmonary vascular
disease based only on sPAP elevation upon exercise, as
diastolic dysfunction is very prevalent in patients with SSc
(at least when assessed using E/e’). In the future, multi-
parametric algorithms may enable a more accurate
diagnosis of diastolic dysfunction [35], namely, not only
based on a single parameter, but also including clinical
factors (such as the presence of hypertension, atrial
fibrillation, diabetes or obesity), electrocardiographic
data and echocardiographic markers of long-standing
elevated LV filling pressures (such as LA area or the
presence of LV hypertrophy) [44].
Due to the concurrent need for assessing CO along
with pulmonary pressures and the limitations of estab-
lishing a diagnosis with only one sPAP value collected at
some time point, a better method for evaluating the
pressure-flow relationship in the pulmonary circulation
might be by the analysis of ΔPAP/ΔCO slopes (i.e., total
pulmonary resistance, TPR), calculated by the measure-
ment of several pressure-flow points throughout the
exercise period [10, 45]. An abnormal response to exer-
cise is signalled by an mPAP >30 mmHg with an mPAP/
CO slope >3 mmHg.L.-1.min-1 [3]. Steeper slopes were
found in patients with SSc compared with controls [46].
Importantly, this calculation does not take in consider-
ation LVEDP; therefore, it is unable to differentiate pre-
capillary from post-capillary EIPH.
Definition of a positive result on exercise
echocardiography
The invasive right heart catheterization-based definition of
EIPH (mPAP >30 mmHg) was abandoned in 2008 due to
limited supporting data [11]. Similarly, for echo-derived
sPAP, there is no consensus on an sPAP cutoff to identify a
“hypertensive response”. This led to different definitions of
what was a positive test in almost all studies. Some assessed
the proportion of patients who achieved a predetermined
exercise sPAP over a cutoff (mostly in the 40–50 mmHg
range), whereas others analysed the variation/increase in
sPAP during exercise. RAP estimation also varied among
studies, adding more variability. These variable definitions
are important limitations of exercise echocardiography.
Additionally, for a result be considered positive, it should
be correlated with a clinical outcome, such as faster pro-
gression to resting PAH. However, there are few data on
the natural history of EIPH. Two RHC-based studies, with
a total of 66 patients with pre-capillary EIPH, observed a
PAH incidence of 8–19 % after 2 years [47, 48]. Two recent
echocardiographic-based studies are available. A 3.5-year
follow up of 170 patients from the cohort of D’Alto et al.
identified 6 patients (3.5 %) with incident resting PH [49].
Of these, three developed group-2 PH, one developed
group-3 PH and three developed PAH. Among the three
patients with PAH, only one had an increase in sPAP
>18 mmHg during the index exercise echocardiogram.
Recently, another study followed up 40 patients with SSc
who had previously undergone exercise echocardiography
[50]. After 2 years, 28 % developed resting PH, all belong-
ing to the group of patients with EIPH at the index evalu-
ation. In this cohort, the development of resting PH was
associated with factors suggestive of latent LV diastolic
dysfunction. The large variation in PH incidence might be
related to the absence of confirmation of resting PH by
RHC in this latter study. In summary, any variable used to
define a positive exercise echocardiographic test has to (1)
accurately reflect the pulmonary vascular reserve, which
may be achieved using multipoint ΔPAP/ΔCO slopes
instead of an isolated sPAP cutoff [51]; (2) integrate infor-
mation on diastolic function markers, which may be
accomplished using a multi-parametric approach for the
estimation of LV filling pressures, using E/e’ but also other
imaging targets, such as mitral propagation velocity (Vp),
diastolic times, pulmonary vein flow measurements or
twist analysis [35]; and (3) to be related to outcomes [52].
The ΔPAP/ΔCO slope method that is associated with a
comprehensive diastolic function assessment is probably
the best suited to comply with all those requirements.
Other factors to consider
There are also other factors that may influence the
results, such as differences in age, gender, athletic cap-
ability or levels of adrenergic response among patients
[8, 17, 53, 54]. Interstitial lung disease and persistent
hypoxia and/or systemic hypertension may also interfere
with exercise-induced sPAP [4, 17, 22, 23]. Usually,
DLCO is lower in patients with SSc-associated PAH that
than in those with idiopathic PAH [55]. This marker,
therefore, is considered a valuable predictor of future
PAH in SSc, decreasing for 10–15 years before a diagno-
sis of PAH is made and reaching a mean of 35 % of the
predicted value at the time of diagnosis [56–58]. Two
authors reported association between lower DLCO and
greater risk of developing exercise-induced elevation in
estimated sPAP [19, 27]. Although this finding may sug-
gest a common pathophysiological mechanism for both
DLCO impairment and exercise PH, further longitudinal
studies need to be performed to clarify this relationship.
Lung fibrosis is also associated with a pulmonary hyper-
tensive response to exertion. In the study by D’Alto et al.
patients with moderate interstitial lung disease had higher
estimated sPAP on exertion than patients without lung
disease (39.7 ± 9.3 vs. 36.0 ± 8.4 mm Hg, p = 0.016). Once
more, several mechanisms can contribute to the elevation
of pulmonary pressures during exercise and it is difficult
to clearly quantify the contribution of each one of them
alone.
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Limitations
As with most systematic reviews, our study is limited by
publication bias that may have supported the utility of
exercise echocardiography for this indication. We tried
to minimize the risk of bias by conducting an extensive
search for potentially relevant studies and reviewing all
bibliographic references.
Future perspectives
There is increasing recognition that EIPH may represent a
preclinical sign of resting PAH. The standardization of
exercise echocardiography for this indication is underway,
with several multi-centric initiatives promoting develop-
ment of a simple and reliable protocol. Concurrently, pro-
spective studies are progressively validating the concept
that abnormal responses to exercise, measured with the
integration of pressure and flow variables, are associated
with a higher incidence of PAH. These studies will provide
data to define diagnostic cutoffs that will stratify risk in
individual patients and indicate which mechanisms of
EIPH (reduced pulmonary reserve or diastolic dysfunc-
tion) are the most important in each subject, therefore
guiding targeted treatments. Ideally, exercise should be
performed in a semi-supine cycloergometer using a ramp
protocol, aiming to measure pressure-flow relationships
during exertion. Further research will then focus on
prophylactic therapeutic interventions aiming to reduce
the incidence of PAH in patients at risk.
Conclusions
In summary, although exercise echocardiography has a
strong rationale in the setting of patients with SSc, we
found relevant heterogeneity in the methods, the proto-
cols, the expected response to yield a positive result, and
critically, no robust data on the prognostic validation of
the EIPH concept. Also, the mechanisms whereby pul-
monary pressures increase during exercise (either due to
PVD, LV diastolic dysfunction, lung disease or a high CO)
must be clearly defined and quantified for each patient
before the results are to be translated into clinical practice.
Current research is addressing those issues to provide a
safe, non-invasive tool for preclinical screening of pul-
monary vascular disease in patients with systemic sclerosis
in the near future.
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